CoChat

Identification of an Acinetobacter baumannii Zinc Acquisition System that Facilitates Resistance to Calprotectin-mediated Zinc Sequestration

Open access

The DOI matches its Crossref record; 63 of the 64 references it cites were found in a registry or an index.

Abstract

Acinetobacter baumannii is an important nosocomial pathogen that accounts for up to 20 percent of infections in intensive care units worldwide. Furthermore, A. baumannii strains have emerged that are resistant to all available antimicrobials. These facts highlight the dire need for new therapeutic strategies to combat this growing public health threat. Given the critical role for transition metals at the pathogen-host interface, interrogating the role for these metals in A. baumannii physiology and pathogenesis could elucidate novel therapeutic strategies. Toward this end, the role for calprotectin- (CP)-mediated chelation of manganese (Mn) and zinc (Zn) in defense against A. baumannii was investigated. These experiments revealed that CP inhibits A. baumannii growth in vitro through chelation of Mn and Zn. Consistent with these in vitro data, Imaging Mass Spectrometry revealed that CP accompanies neutrophil recruitment to the lung and accumulates at foci of infection in a murine model of A. baumannii pneumonia. CP contributes to host survival and control of bacterial replication in the lung and limits dissemination to secondary sites. Using CP as a probe identified an A. baumannii Zn acquisition system that contributes to Zn uptake, enabling this organism to resist CP-mediated metal chelation, which enhances pathogenesis. Moreover, evidence is provided that Zn uptake across the outer membrane is an energy-dependent process in A. baumannii. Finally, it is shown that Zn limitation reverses carbapenem resistance in multidrug resistant A. baumannii underscoring the clinical relevance of these findings. Taken together, these data establish Zn acquisition systems as viable therapeutic targets to combat multidrug resistant A. baumannii infections.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.ppat.1003068

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 CP inhibits A. baumannii growth in vitro through chelation of Mn and Zn. (A) A. baumannii growth in the presence of increasing concentrations of CP with (dashed lines) or without (solid lines) 25 µM Mn and 25 µM Zn added back. Data represent the average of three biological replicates. (B) Treatment with CP reduces intracellular Mn and Zn accumulation. ICP-MS analyses of intracellular Mn, Fe and Zn expressed as the relative ratio compared to intracellular Cu. ** p<0.01, *** p<0.001 by two-way ANOVA.
Figure 1 CP inhibits A. baumannii growth in vitro through chelation of Mn and Zn. (A) A. baumannii growth in the presence of increasing concentrations of CP with (dashed lines) or without (solid lines) 25 µM Mn and 25 µM Zn added back. Data represent the average of three biological replicates. (B) Treatment with CP reduces intracellular Mn and Zn accumulation. ICP-MS analyses of intracellular Mn, Fe and Zn expressed as the relative ratio compared to intracellular Cu. ** p<0.01, *** p<0.001 by two-way ANOVA.CC BY · PubMed Central
Figure 2 CP contributes to protection against A. baumannii infection. (A–B) IMS detection of host proteins in lungs harvested at 36 hpi with A. baumannii. Scale bar = 2 cm. (A) Heat map demonstrating the distribution and abundance of S100A8 (m/z = 10,165.8±5 Da) in uninfected wildtype (left) and infected wildtype (middle) or S100A9−/− (right) mice. (B) Heat map demonstrating the distribution and abundance of a protein exhibiting m/z 5,679±5 Da in uninfected wildtype (left) and infected wildtype (middle) or S100A9−/− (right) mice. (C–F) Hematoxylin and eosin stained histological sections taken from lungs harvested at 36 hpi from mice infected with A. baumannii. (C, E) Wildtype C57BL/6. (D, F) S100A9−/−. Scale bars equal 500 µm (C–D) and 50 µm (E–F). Images are representative of sections taken from three mice for each genotype. (G) Survival of wildtype or CP-deficient mice following infection with A. baumannii. Data were combined from three independent experiments with 8–16 mice per group in each experiment. ** p<0.01 as determined by Gehan-Breslow-Wilcoxon Test. (H) Bacterial burden in lungs and livers of wildtype or CP-deficient mice 36 hpi with A. baumannii. Data were averaged from three independent experiments with 5–10 mice per group in each experiment. ** p<0.01 as determined by Student's t test.
Figure 2 CP contributes to protection against A. baumannii infection. (A–B) IMS detection of host proteins in lungs harvested at 36 hpi with A. baumannii. Scale bar = 2 cm. (A) Heat map demonstrating the distribution and abundance of S100A8 (m/z = 10,165.8±5 Da) in uninfected wildtype (left) and infected wildtype (middle) or S100A9−/− (right) mice. (B) Heat map demonstrating the distribution and abundance of a protein exhibiting m/z 5,679±5 Da in uninfected wildtype (left) and infected wildtype (middle) or S100A9−/− (right) mice. (C–F) Hematoxylin and eosin stained histological sections taken from lungs harvested at 36 hpi from mice infected with A. baumannii. (C, E) Wildtype C57BL/6. (D, F) S100A9−/−. Scale bars equal 500 µm (C–D) and 50 µm (E–F). Images are representative of sections taken from three mice for each genotype. (G) Survival of wildtype or CP-deficient mice following infection with A. baumannii. Data were combined from three independent experiments with 8–16 mice per group in each experiment. ** p<0.01 as determined by Gehan-Breslow-Wilcoxon Test. (H) Bacterial burden in lungs and livers of wildtype or CP-deficient mice 36 hpi with A. baumannii. Data were averaged from three independent experiments with 5–10 mice per group in each experiment. ** p<0.01 as determined by Student's t test.CC BY · PubMed Central
Figure 3 Transposon library screen to identify bacterial processes affected by CP treatment. (A) Bacterial growth from a representative plate of mutants cultured in media alone or media with 40 µg/ml CP. Data for wells in which no bacterial growth was observed in either condition have been omitted. Red symbols indicate mutants selected for secondary screening (see Materials and Methods). (B) Growth of selected mutants relative to wildtype bacteria cultured in media alone or media containing 40 µg/ml CP. Mutants are classified according to the predicted functional category of the gene disrupted by the transposon. ** p<0.01, *** p<0.001 for relative growth in the presence of CP compared to media alone, as determined by two-way ANOVA. (C) Growth curves comparing wildtype A. baumannii and znuB::Tn5 in the presence or absence of 25 µg/ml CP. IC50 values were determined as described in the Materials and Methods.
Figure 3 Transposon library screen to identify bacterial processes affected by CP treatment. (A) Bacterial growth from a representative plate of mutants cultured in media alone or media with 40 µg/ml CP. Data for wells in which no bacterial growth was observed in either condition have been omitted. Red symbols indicate mutants selected for secondary screening (see Materials and Methods). (B) Growth of selected mutants relative to wildtype bacteria cultured in media alone or media containing 40 µg/ml CP. Mutants are classified according to the predicted functional category of the gene disrupted by the transposon. ** p<0.01, *** p<0.001 for relative growth in the presence of CP compared to media alone, as determined by two-way ANOVA. (C) Growth curves comparing wildtype A. baumannii and znuB::Tn5 in the presence or absence of 25 µg/ml CP. IC50 values were determined as described in the Materials and Methods.CC BY · PubMed Central
Figure 4 Contribution of znuB to growth in Zn-limiting conditions. (A) Schematic representation of the genomic context adjacent to A1S_0143. (B) CP growth inhibition assays comparing wildtype with ΔznuB. Bacteria were cultured in CP growth media in the presence of increasing concentrations of CP with or without addition of 25 µM Zn, 25 µM Mn or both 25 µM Zn and 25 µM Mn. Data for 100 µg/ml CP are presented as the percent growth relative to bacterial growth without CP. Data are the average of three independent experiments with at least three biological replicates each. (C) Comparison of the effect of 25 µM TPEN on inhibition of wildtype and ΔznuB with or without addition of excess (50 µM) Zn. (D) Complementation of the sensitivity of ΔznuB to 20 µM TPEN by providing a wildtype copy of znuB in trans. Data are representative of three independent experiments with at least three biological replicates in each. * p<0.05, ** p<0.01, *** p<0.001 as determined by one-way ANOVA. (E–F) Assessment of znu promoter activity in the presence of increasing concentrations of TPEN (E) or Zn (F) using a GFP reporter. GFP activity is expressed as relative fluorescence where the intensity of the signal is normalized to the optical density of the culture.
Figure 4 Contribution of znuB to growth in Zn-limiting conditions. (A) Schematic representation of the genomic context adjacent to A1S_0143. (B) CP growth inhibition assays comparing wildtype with ΔznuB. Bacteria were cultured in CP growth media in the presence of increasing concentrations of CP with or without addition of 25 µM Zn, 25 µM Mn or both 25 µM Zn and 25 µM Mn. Data for 100 µg/ml CP are presented as the percent growth relative to bacterial growth without CP. Data are the average of three independent experiments with at least three biological replicates each. (C) Comparison of the effect of 25 µM TPEN on inhibition of wildtype and ΔznuB with or without addition of excess (50 µM) Zn. (D) Complementation of the sensitivity of ΔznuB to 20 µM TPEN by providing a wildtype copy of znuB in trans. Data are representative of three independent experiments with at least three biological replicates in each. * p<0.05, ** p<0.01, *** p<0.001 as determined by one-way ANOVA. (E–F) Assessment of znu promoter activity in the presence of increasing concentrations of TPEN (E) or Zn (F) using a GFP reporter. GFP activity is expressed as relative fluorescence where the intensity of the signal is normalized to the optical density of the culture.CC BY · PubMed Central
Figure 5 Genetic characterization of a putative Zn uptake system in A. baumannii. (A) Schematic representation of the genomic locus containing znuA and the zurznuCB operon. The sequence corresponding to a putative zur box is shown. (B) PAR assay measuring Zn binding by Zur. Spectral scans of solutions containing 10 µM PAR without Zn (black line), with Zn (blue line) or with Zn and increasing concentrations of Zur (green lines) are shown. (C–D) EMSA assays measuring binding of Zur to Zur target DNA (C) or negative control DNA (D) in the presence of Zn. (E) EMSA assay demonstrating loss of Zur binding to target DNA in the presence of increasing concentrations of EDTA. Arrow indicates mobility of shifted band. (F) Consensus sequence for the A. baumannii Zur box. (G) Predicted Zur-regulated genes and their predicted Zur boxes. (H) Expression analyses of genes predicted to be involved in Zn uptake across the outer (znuD1, znuD2, TonB1) and inner (znuA, znuB, znuC) membranes. Asterisks indicate relative expression that is statistically greater than one, where 1-fold indicates no change in expression in TPEN treated bacteria compared to untreated bacteria. * p<0.05, ** p<0.01 as determined by one sample t test using a reference value of one.
Figure 5 Genetic characterization of a putative Zn uptake system in A. baumannii. (A) Schematic representation of the genomic locus containing znuA and the zurznuCB operon. The sequence corresponding to a putative zur box is shown. (B) PAR assay measuring Zn binding by Zur. Spectral scans of solutions containing 10 µM PAR without Zn (black line), with Zn (blue line) or with Zn and increasing concentrations of Zur (green lines) are shown. (C–D) EMSA assays measuring binding of Zur to Zur target DNA (C) or negative control DNA (D) in the presence of Zn. (E) EMSA assay demonstrating loss of Zur binding to target DNA in the presence of increasing concentrations of EDTA. Arrow indicates mobility of shifted band. (F) Consensus sequence for the A. baumannii Zur box. (G) Predicted Zur-regulated genes and their predicted Zur boxes. (H) Expression analyses of genes predicted to be involved in Zn uptake across the outer (znuD1, znuD2, TonB1) and inner (znuA, znuB, znuC) membranes. Asterisks indicate relative expression that is statistically greater than one, where 1-fold indicates no change in expression in TPEN treated bacteria compared to untreated bacteria. * p<0.05, ** p<0.01 as determined by one sample t test using a reference value of one.CC BY · PubMed Central
Figure 6 Contribution of the Znu system to pathogenesis in vivo. (A–F) In vivo GFP expression driven by the znu promoter. Frozen sections of lungs harvested at 36 hpi from wildtype (A–C) or S100A9−/− (D–F) mice infected with WT::pznuGFP and stained with DAPI. Arrowheads in the merged images indicate bacteria expressing GFP. (G–H) Competition infection between wildtype and ΔznuB. Bacterial burden in lungs (G) and livers (H) of mice co-infected with wildtype A. baumannii and ΔznuB. Red symbols indicate CFU below the limit of detection. * p<0.05, ** p<0.01, *** p<0.001 as determined by one-way ANOVA.
Figure 6 Contribution of the Znu system to pathogenesis in vivo. (A–F) In vivo GFP expression driven by the znu promoter. Frozen sections of lungs harvested at 36 hpi from wildtype (A–C) or S100A9−/− (D–F) mice infected with WT::pznuGFP and stained with DAPI. Arrowheads in the merged images indicate bacteria expressing GFP. (G–H) Competition infection between wildtype and ΔznuB. Bacterial burden in lungs (G) and livers (H) of mice co-infected with wildtype A. baumannii and ΔznuB. Red symbols indicate CFU below the limit of detection. * p<0.05, ** p<0.01, *** p<0.001 as determined by one-way ANOVA.CC BY · PubMed Central
Figure 7 Effect of Zn chelation on resistance to imipenem and levofloxacin in an MDR isolate of A. baumannii. Bacterial growth measured at 24 hours in LB medium in the presence of increasing concentrations of imipenem (A) or levofloxacin (B) and 25 µM TPEN, with or without addition of excess Zn. Data for concentrations near and above the clinical breakpoints for resistance are shown.
Figure 7 Effect of Zn chelation on resistance to imipenem and levofloxacin in an MDR isolate of A. baumannii. Bacterial growth measured at 24 hours in LB medium in the presence of increasing concentrations of imipenem (A) or levofloxacin (B) and 25 µM TPEN, with or without addition of excess Zn. Data for concentrations near and above the clinical breakpoints for resistance are shown.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

5 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 63 references

Cited by

See all 274

Metadata

Authors
Hood, M. I., Mortensen, B. L., Moore, J. L., Zhang, Y., Kehl-Fie, T. E., Sugitani, N., Chazin, W. J., Caprioli, R. M., & Skaar, E. P.
Affiliations
Vanderbilt University (US)
Corresponding author
Skaar, Eric P.
Venue
PLoS Pathogens
Published
2012-12-06
Volume
8
Issue
12
Pages
e1003068
ISSN
  • 1553-7366 (ISSN-L)
  • 1553-7374
OpenAlex
W2016802844
Cited by
255
References
64
Citations by year
2026: 7 · 2025: 16 · 2024: 13 · 2023: 16 · 2022: 13 · 2021: 26 · 2020: 20 · 2019: 25 · 2018: 16 · 2017: 26 · 2016: 23 · 2015: 20 · 2014: 20 · 2013: 14
FWCI
10.24
Type
journal article
Language
en
Open access
Locations
  • PLoS Pathogens (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
  • Howard Hughes Medical Institute
  • American Heart Association
  • Vanderbilt University (T32 GM07347)
  • University of Miami
  • Case Western Reserve University
  • National Institutes of Health
  • U.S. Public Health Service (8P41GMI03391-2)
  • National Institute of General Medical Sciences (T32GM065086, GM 07347, T32GM008320, T32GM007347)
  • National Institute of Allergy and Infectious Diseases (R56AI091771, T32AI095202)
  • National Center for Research Resources (P41RR031461)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
  • Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › S100 Proteins and Annexins
Keywords
Acinetobacter baumannii, calprotectin, metal chelation, zinc limitation, manganese, carbapenem resistance, multidrug resistance, neutrophil recruitment, pneumonia, therapeutic target, transition metals
MeSH terms
Acinetobacter Infections, Animals, Biological Transport, Active, Disease Models, Animal, Humans, Lung, Manganese, Neutrophils, Zinc, Carbapenems, Mice, Knockout, Pneumonia, Bacterial, Neutrophil Infiltration, Drug Resistance, Multiple, Bacterial, Leukocyte L1 Antigen Complex, Acinetobacter baumannii, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.